Reuters logo
BRIEF-U.S. FDA approved Amgen's Mvasi as a biosimilar to Avastin
September 14, 2017 / 4:36 PM / 2 months ago

BRIEF-U.S. FDA approved Amgen's Mvasi as a biosimilar to Avastin

Sept 14 (Reuters) - U.S. FDA

* U.S. FDA says approved Amgen’s Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer

* ‍U.S. FDA says Mvasi is approved for the treatment of adult patients with certain colorectal, lung, brain, kidney and cervical cancers​ Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below